News About: Pharm. Affairs
Collective drug sales on Sep., KRW 10.1113 trillion increased by 4.5%
The amount of pharmaceutical sales was KRW 1.1024 trillion on September, and this year’s amount is estimated at KRW 13.5663 trillion.
Through an analysis report on the 1st, Shinhan Investment Corp. announced the amo...
Celltrion applies approval of antibody biosimilar ‘Herzuma’ to EMAOn the 27th of October(local time), Celltrion announced the application for approval of the antibody biosimilar to treat breast cancer, ‘Herzuma,’ was officially accepted at the...
|
Hanmi announces start on Phase 3 clinical trials for ‘efpeglenatide’ in 2017
On the 28th, Hanmi Pharm(CEO Kwan-Soon Lee) announced it plans to start Phase 3 clinical trials of a new antidiabetic, whose license was agreed with Sanofi last year, ‘efpeglenatide,’ in 2017.
Hanmi Pharm and Sanofi...
Korean companies might face ‘global trails’ due to late responses to ‘urgent’ Nagoya Protocol
Even in Korea, it was criticized companies should more actively response to the Nagoya Protocol; this is because they might get involved in ‘global lawsuits.’
In the ‘Has everyone been getting ready for the urgent N...
No. of OTC drugs to keep dropping every year
The number and amount of OTC drugs manufactured are observed to decrease.
According to the Ministry of Food and Drug Safety(MFDS), it was observed the number of pharmaceutical products manufactured in 2015 was 17,907...
Hanlim wins 2nd trial for Allergan’s ‘Combigan’ composition patent, too
Hanlim Pharm, which filed the nullification trial of the glaucoma-treating ‘Combigan’ composition patent, won the 2nd trial, too, against Allergan owning the original product.
This winning has raise the chance for Ha...
Baraclude directly suffering from 53.55% price cuts
A hepatitis B treatment which had kept the No. 1 position in the prescription market for several years, ‘Baraclude’ is now experiencing sharp decreases in prescription in a year of its patent expiration.
It is true i...
‘Hidden champions,’ Japanese pharmas to target Korean market
Japanese pharmaceutical companies branched in Korea are on a roll, showing themselves as ‘hidden champions’ in the Korean industry. Although they are not as global as international companies such as Novartis and Pfize...
No. of pharmacies was 21,267 in 2015, increased by 209
The Health Insurance Review & Assessment Service(Director Myung-Sae Sohn) and the National Health Insurance Service(President Sang-Cheol Sung) published the ‘2015 Year Book for National Health Insurance Statistics’ wh...
“Why Korean companies ignore KRW 130 billion ‘Lipitor’”
While the complex market with statin has led the industry, Korean pharmaceutical companies are known to focus, especially, on R&D for ‘Crestor(generic name: rosuvastatin).’
In this way, the market of combined drugs w...
